Browsing Tag
Caribou Biosciences
3 posts
Why is Caribou Biosciences ending CAR-T development before a planned phase 3 trial?
Caribou Biosciences is winding down its allogeneic CAR-T programmes and sharply reducing its workforce after financing constraints overtook clinical progress, leaving $113.8 million of mid-year liquidity and its genome-editing assets at the centre of a strategic review.
Caribou Biosciences set for key webcast showcasing CRISPR-engineered CAR-T breakthroughs in blood cancers
Discover how Caribou Biosciences is preparing to reveal breakthrough CRISPR-edited allogeneic CAR-T data in lymphoma and myeloma during its investor webcast.
Caribou Biosciences launches CB-010 GALLOP Phase 1 trial in lupus
Caribou Biosciences, Inc., a clinical-stage leader in CRISPR genome-editing biopharmaceuticals, has announced the initiation of its CB-010 GALLOP…